Forty-three subjects with B-cell acute lymphoblastic leukemia relapsing post allotransplant received CAR-T cells were analyzed.
6445218 SJ5J2GSZ items 1 apa default asc 1
Zhang, C., Wang, X.-Q., Zhang, R.-L., Liu, F., Wang, Y., Yan, Z.-L., Song, Y.-P., Yang, T., Li, P., Wang, Z., Ma, Y.-Y., Gao, L., Liu, Y., Gao, L., Kong, P.-Y., Liu, J., Tan, X., Zhong, J. F., Chen, Y.-Q., … Zhang, X. (2020). Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia, 1–8. https://doi.org/10.1038/s41375-020-01056-6 Cite
Pluristem Therapeutics Inc. announced that it has received clearance from the safety committee of an investigator initiated Phase I/II study to move forward with patient enrollment for cohort II. The study will evaluate PLX-PAD cells in the treatment of steroid-refractory chronic graft vs. host disease and is led by Principal Investigator Prof. Ron Ram, Director of the Hematology Blood and Marrow Stem Cell Transplantation Unit at Tel Aviv Sourasky Medical Center, Ichilov Hospital, Israel.
[Pluristem Therapeutics Inc.]
6445212 nan items 1 apa default asc 1
The authors describe the role of allogeneic hematopoietic stem cell transplantation in cutaneous T-cell lymphomas, and summarize the published data and future perspectives in this area.
Scientists retrospectively analyzed 4392 patients with leukemia or myelodysplastic syndrome who received transplants from human leukocyte antigen (HLA)-identical sibling donors to investigate the effects of HLAs on acute graft-versus-host disease.
[Bone Marrow Transplantation]
1254621 NMIPJ8LW items 1 apa default asc 1
Morishima, S., Fukuda, T., Doki, N., Mori, T., Onizuka, M., Kawakita, T., Kato, C., Ozawa, Y., Tanaka, M., Kurokawa, M., Kamimura, T., Inoue, M., Tanaka, J., Ichinohe, T., Atsuta, Y., & Morishima, Y. (2020). Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors. Bone Marrow Transplantation, 1–9. https://doi.org/10.1038/s41409-020-01070-3 Cite
Scientists report a new patient with a novel frameshift mutation and compared this patient with the previously reported SMARCD2-mutant patients, aiming to provide a more comprehensive understanding of the natural course of the disease.
[Journal of Clinical Immunology]
1254621 X4RKC3ZJ items 1 apa default asc 1
Yucel, E., Karakus, I. S., Krolo, A., Kiykim, A., Heredia, R. J., Tamay, Z., Cipe, F. E., Karakoc-Aydiner, E., Ozen, A., Karaman, S., Boztug, K., & Baris, S. (2020). Novel Frameshift Autosomal Recessive Loss-of-Function Mutation in SMARCD2 Encoding a Chromatin Remodeling Factor Mediates Granulopoiesis. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-020-00878-4 Cite
No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia prior to allogeneic hematopoietic cell transplantation. To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor failure researchers performed a retrospective EBMT registry-based study.
[Bone Marrow Transplantation]
6445218 P2M853EY items 1 apa default asc 1
Schetelig, J., Chevallier, P., van Gelder, M., Hoek, J., Hermine, O., Chakraverty, R., Browne, P., Milpied, N., Malagola, M., Socié, G., Delgado, J., Deconinck, E., Damaj, G., Maury, S., Beelen, D., Quoc, S. N., Shankara, P., Brecht, A., Mayer, J., … Dreger, P. (2020). Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. Bone Marrow Transplantation, 1–9. https://doi.org/10.1038/s41409-020-01069-w Cite
Investigators studied 937 patients with acute myeloid leukaemia in complete remission transplanted using a reduced intensity conditioning regimen from an unrelated donor mismatched at a single allele.
[Bone Marrow Transplantation]
6445218 8GH8UGUN items 1 apa default asc 1
Loke, J., Labopin, M., Craddock, C., Niederwieser, D., Cornelissen, J., Afansayev, B., Jindra, P., Maertens, J., Blaise, D., Boriskina, K., Gramatzki, M., Ganser, A., Savani, B., Mohty, M., & Nagler, A. (2020). Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT. Bone Marrow Transplantation, 1–8. https://doi.org/10.1038/s41409-020-01072-1 Cite
The authors showed that in vivo IRX4204 was compared favorably with FK506 in abrogating acute graft-versus-host disease, which was associated with inhibiting allogeneic donor T cell proliferation, reducing T helper 1 differentiation and promoting regulatory T cell generation.
6445218 KMIXK3N9 items 1 apa default asc 1
Thangavelu, G., Wang, C., Loschi, M., Saha, A., Osborn, M., Furlan, S. N., Aoyama, K., McDonald-Hyman, C., Aguilar, E. G., Janesick, A. S., Chandraratna, R. A., Refaeli, Y., Panoskaltsis-Mortari, A., MacDonald, K. P., Hill, G. R., Zeiser, R., Maillard, I., Serody, J., Murphy, W. J., … Blazar, B. R. (n.d.). Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses. Blood. https://doi.org/10.1182/blood.2020005628 Cite
The authors examine the various factors to be considered when developing a hMSC manufacturing process using microcarriers and bioreactors and their potential impact on the final product.
6445212 R4YHWR64 items 1 apa default asc 1
Silva Couto, P., Rotondi, M. C., Bersenev, A., Hewitt, C. J., Nienow, A. W., Verter, F., & Rafiq, Q. A. (2020). Expansion of human mesenchymal stem/stromal cells (hMSCs) in bioreactors using microcarriers: lessons learnt and what the future holds. Biotechnology Advances, 107636. https://doi.org/10.1016/j.biotechadv.2020.107636 Cite
Cardiovascular cells derived from muscular dystrophy patients’ iPSCs are well suited to mimic dystrophin-associated cardiomyopathy and hold great promise for the development of future fully effective therapies. This article conveys the realities of employing precision disease models of dystrophin-associated cardiomyopathy.
[International Journal of Molecular Sciences]
Outpatient second hematoprogenitors transplant after reduced‐intensity conditioning at a single academic center was analyzed. Twenty‐seven consecutive adults who received an allogeneic hematopoietic stem cell transplantation (allo‐HSCT) after an initial auto‐ or allo‐HSCT from 2006 to 2019 were included.
1254621 FPRAGLMC items 1 apa default asc 1